10x fund lp - by 10x fund lp investment history in Pro pharmaceuticals inc

Filed on 2010-05-12 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000008.txt Sec File: edgar/data/1457247/0001457247-10-000008-index.htm

2010-05-10 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 11

Class B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-05-10 exercise price 0.5 has valueitem expiration due date 2015-05-10 underlying security shares 2280000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 285,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 570,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 570,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,280,000 shares of common stock for $0.50 per share, for aggregate consideration of $570,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2010-05-12 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000008.txt Sec File: edgar/data/1457247/0001457247-10-000008-index.htm

2010-05-10 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 11

Class A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-05-10 exercise price 0.5 has valueitem expiration due date 2015-05-10 underlying security shares 570000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 285,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 570,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 570,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,280,000 shares of common stock for $0.50 per share, for aggregate consideration of $570,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2010-05-12 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000008.txt Sec File: edgar/data/1457247/0001457247-10-000008-index.htm

2010-05-10 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 11

Class A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-05-10 exercise price 0.5 has valueitem expiration due date 2015-05-10 underlying security shares 570000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 285,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 570,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 570,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,280,000 shares of common stock for $0.50 per share, for aggregate consideration of $570,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2010-05-12 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000008.txt Sec File: edgar/data/1457247/0001457247-10-000008-index.htm

2010-05-10 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 285000 shares at $2 remaining shares owned 2100000

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 1140000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 285,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 570,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 570,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,280,000 shares of common stock for $0.50 per share, for aggregate consideration of $570,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f1 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after may 10, 2011 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.


Filed on 2010-05-07 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000005.txt Sec File: edgar/data/1457247/0001457247-10-000005-index.htm

2010-04-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 10

Class B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-04-30 exercise price 0.5 has valueitem expiration due date 2015-04-30 underlying security shares 1240000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 285,000 shares of series b-2 preferred stock convertible into 1,140,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 570,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 570,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 2,280,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009 and february 11, 2010, between issuer and 10x fund, l.p.


Filed on 2010-05-07 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000005.txt Sec File: edgar/data/1457247/0001457247-10-000005-index.htm

2010-04-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 10

Class A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-04-30 exercise price 0.5 has valueitem expiration due date 2015-04-30 underlying security shares 310000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 285,000 shares of series b-2 preferred stock convertible into 1,140,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 570,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 570,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 2,280,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009 and february 11, 2010, between issuer and 10x fund, l.p.


Filed on 2010-05-07 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000005.txt Sec File: edgar/data/1457247/0001457247-10-000005-index.htm

2010-04-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 10

Class A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-04-30 exercise price 0.5 has valueitem expiration due date 2015-04-30 underlying security shares 310000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 285,000 shares of series b-2 preferred stock convertible into 1,140,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 570,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 570,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 2,280,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009 and february 11, 2010, between issuer and 10x fund, l.p.


Filed on 2010-05-07 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001457247-10-000005.txt Sec File: edgar/data/1457247/0001457247-10-000005-index.htm

2010-04-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 155000 shares at $2 remaining shares owned 1815000

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 620000 underlying security title Common Stock

f2 on april 30, 2010, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 285,000 shares of series b-2 preferred stock convertible into 1,140,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 570,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 570,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 2,280,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009 and february 11, 2010, between issuer and 10x fund, l.p.
f1 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after april 30, 2011 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.


Filed on 2010-03-12 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000006.txt Sec File: edgar/data/1457247/0001453356-10-000006-index.htm

2010-03-08 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 9

Series B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-03-08 exercise price 0.5 has valueitem expiration due date 2015-03-08 underlying security shares 1340000 underlying security title Common Stock

f2 on march 8, 2010, 10x fund, l.p. purchased (a) 167,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 335,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 335,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,340,000 shares of common stock for $0.50 per share, for aggregate consideration of $335,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 440,000 shares of series b-2 preferred stock convertible into 1,760,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 880,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 880,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 3,520,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009 and february 11, 2009, between issuer and 10x fund, l.p.


Filed on 2010-03-12 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000006.txt Sec File: edgar/data/1457247/0001453356-10-000006-index.htm

2010-03-08 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 9

Series A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-03-08 exercise price 0.5 has valueitem expiration due date 2015-03-08 underlying security shares 335000 underlying security title Common Stock

f2 on march 8, 2010, 10x fund, l.p. purchased (a) 167,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 335,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 335,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,340,000 shares of common stock for $0.50 per share, for aggregate consideration of $335,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 440,000 shares of series b-2 preferred stock convertible into 1,760,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 880,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 880,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 3,520,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009 and february 11, 2009, between issuer and 10x fund, l.p.


Filed on 2010-03-12 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000006.txt Sec File: edgar/data/1457247/0001453356-10-000006-index.htm

2010-03-08 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 9

Series A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-03-08 exercise price 0.5 has valueitem expiration due date 2015-03-08 underlying security shares 335000 underlying security title Common Stock

f2 on march 8, 2010, 10x fund, l.p. purchased (a) 167,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 335,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 335,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,340,000 shares of common stock for $0.50 per share, for aggregate consideration of $335,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 440,000 shares of series b-2 preferred stock convertible into 1,760,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 880,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 880,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 3,520,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009 and february 11, 2009, between issuer and 10x fund, l.p.


Filed on 2010-02-02 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000001.txt Sec File: edgar/data/1457247/0001453356-10-000001-index.htm

2010-01-29 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 8

Class B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-01-29 exercise price 0.5 has valueitem expiration due date 2015-01-29 underlying security shares 1300000 underlying security title Common Stock

f3 on january 29, 2010, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f4 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f5 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 607,500 shares of series b-2 preferred stock convertible into 2,430,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,215,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,215,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 4,860,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2010-02-02 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000001.txt Sec File: edgar/data/1457247/0001453356-10-000001-index.htm

2010-01-29 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 8

Class A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-01-29 exercise price 0.5 has valueitem expiration due date 2015-01-29 underlying security shares 325000 underlying security title Common Stock

f3 on january 29, 2010, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f4 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f5 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 607,500 shares of series b-2 preferred stock convertible into 2,430,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,215,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,215,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 4,860,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2010-02-02 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000001.txt Sec File: edgar/data/1457247/0001453356-10-000001-index.htm

2010-01-29 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 8

Class A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2010-01-29 exercise price 0.5 has valueitem expiration due date 2015-01-29 underlying security shares 325000 underlying security title Common Stock

f3 on january 29, 2010, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f4 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f5 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 607,500 shares of series b-2 preferred stock convertible into 2,430,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,215,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,215,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 4,860,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2010-02-02 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000001.txt Sec File: edgar/data/1457247/0001453356-10-000001-index.htm

2010-01-29 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 162500 shares at $2 remaining shares owned 1492500

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 650000 underlying security title Common Stock

f3 on january 29, 2010, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f4 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f5 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 607,500 shares of series b-2 preferred stock convertible into 2,430,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,215,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,215,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 4,860,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.
f2 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after december 8, 2010 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.


Filed on 2010-02-02 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-10-000001.txt Sec File: edgar/data/1457247/0001453356-10-000001-index.htm

2009-12-31 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 260027 shares at $0.28 remaining shares owned 680831

Common Stock Pro Pharmaceuticals Inc Prwp Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f1 on december 31, 2009, 10x fund, l.p. received 260,027 shares of common stock of the issuer in satisfaction of dividends on shares of series b-1 and b-2 convertible preferred stock owned by 10x fund, l.p. dividends on the preferred stock are payable in shares of the issuer's common stock valued at $0.50 per share, with regard to the actual market price of the common stock at the time of issuance. the market value of the common stock at the time of its issuance was less than $0.50 per share.


Filed on 2009-12-14 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001456614-09-000015.txt Sec File: edgar/data/1457247/0001456614-09-000015-index.htm

2009-12-08 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 7

Class B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-12-08 exercise price 0.5 has valueitem expiration due date 2014-12-08 underlying security shares 1300000 underlying security title Common Stock

f2 on december 8, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 770,000 shares of series b-2 preferred stock convertible into 3,080,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,540,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,540,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 6,160,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-12-14 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001456614-09-000015.txt Sec File: edgar/data/1457247/0001456614-09-000015-index.htm

2009-12-08 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 7

Class A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-12-08 exercise price 0.5 has valueitem expiration due date 2014-12-08 underlying security shares 325000 underlying security title Common Stock

f2 on december 8, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 770,000 shares of series b-2 preferred stock convertible into 3,080,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,540,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,540,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 6,160,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-12-14 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001456614-09-000015.txt Sec File: edgar/data/1457247/0001456614-09-000015-index.htm

2009-12-08 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 7

Class A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-12-08 exercise price 0.5 has valueitem expiration due date 2014-12-08 underlying security shares 325000 underlying security title Common Stock

f2 on december 8, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 770,000 shares of series b-2 preferred stock convertible into 3,080,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,540,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,540,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 6,160,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-12-14 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001456614-09-000015.txt Sec File: edgar/data/1457247/0001456614-09-000015-index.htm

2009-12-08 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 162500 shares at $2 remaining shares owned 1330000

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 650000 underlying security title Common Stock

f2 on december 8, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 770,000 shares of series b-2 preferred stock convertible into 3,080,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,540,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,540,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 6,160,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.
f1 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after december 8, 2010 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.


Filed on 2009-11-09 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000026.txt Sec File: edgar/data/1457247/0001260641-09-000026-index.htm

2009-11-03 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 6

Series B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-11-03 exercise price 0.5 has valueitem expiration due date 2014-11-03 underlying security shares 1240000 underlying security title Common Stock

f2 on november 3, 2009, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 932,500 shares of series b-2 preferred stock convertible into 3,730,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,865,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,865,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 7,460,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-11-09 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000026.txt Sec File: edgar/data/1457247/0001260641-09-000026-index.htm

2009-11-03 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 6

Series A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-11-03 exercise price 0.5 has valueitem expiration due date 2014-11-03 underlying security shares 310000 underlying security title Common Stock

f2 on november 3, 2009, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 932,500 shares of series b-2 preferred stock convertible into 3,730,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,865,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,865,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 7,460,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-11-09 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000026.txt Sec File: edgar/data/1457247/0001260641-09-000026-index.htm

2009-11-03 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 6

Series A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-11-03 exercise price 0.5 has valueitem expiration due date 2014-11-03 underlying security shares 310000 underlying security title Common Stock

f2 on november 3, 2009, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 932,500 shares of series b-2 preferred stock convertible into 3,730,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,865,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,865,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 7,460,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-11-09 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000026.txt Sec File: edgar/data/1457247/0001260641-09-000026-index.htm

2009-11-03 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 155000 shares at $2 remaining shares owned 1167500

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 620000 underlying security title Common Stock

f2 on november 3, 2009, 10x fund, l.p. purchased (a) 155,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 310,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 310,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,240,000 shares of common stock for $0.50 per share, for aggregate consideration of $310,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 932,500 shares of series b-2 preferred stock convertible into 3,730,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 1,865,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 1,865,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 7,460,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.
f1 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after november 3, 2010 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.


Filed on 2009-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000014.txt Sec File: edgar/data/1457247/0001453356-09-000014-index.htm

2009-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 5

Class B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-09-30 exercise price 0.5 has valueitem expiration due date 2014-09-30 underlying security shares 1300000 underlying security title Common Stock

f5 on september 30, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 1,087,500 shares of series b-2 preferred stock convertible into 4,350,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,175,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,175,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 8,700,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000014.txt Sec File: edgar/data/1457247/0001453356-09-000014-index.htm

2009-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 5

Class A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-09-30 exercise price 0.5 has valueitem expiration due date 2014-09-30 underlying security shares 325000 underlying security title Common Stock

f5 on september 30, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 1,087,500 shares of series b-2 preferred stock convertible into 4,350,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,175,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,175,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 8,700,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000014.txt Sec File: edgar/data/1457247/0001453356-09-000014-index.htm

2009-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 5

Class A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-09-30 exercise price 0.5 has valueitem expiration due date 2014-09-30 underlying security shares 325000 underlying security title Common Stock

f5 on september 30, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 1,087,500 shares of series b-2 preferred stock convertible into 4,350,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,175,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,175,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 8,700,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.


Filed on 2009-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000014.txt Sec File: edgar/data/1457247/0001453356-09-000014-index.htm

2009-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 162500 shares at $2 remaining shares owned 1012500

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 650000 underlying security title Common Stock

f5 on september 30, 2009, 10x fund, l.p. purchased (a) 162,500 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 325,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 325,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,300,000 shares of common stock for $0.50 per share, for aggregate consideration of $325,000.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f6 excludes (i) up to 1,087,500 shares of series b-2 preferred stock convertible into 4,350,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,175,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,175,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 8,700,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009, as amended on august 11, 2009, between issuer and 10x fund, l.p.
f4 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after september 30, 2010 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.


Filed on 2009-10-06 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000014.txt Sec File: edgar/data/1457247/0001453356-09-000014-index.htm

2009-09-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 213136 shares at $0.5 remaining shares owned 420804

Common Stock Pro Pharmaceuticals Inc Prwp Transaction code: A Grant, award, or other acquisition

f1 on september 30, 2009, 10x fund, l.p. received 213,136 shares of common stock of the issuer in satisfaction of dividends on shares of series b-1 and b-2 convertible preferred stock owned by 10x fund, l.p. dividends on the preferred stock are payable in shares of the issuer's common stock valued at $0.50 per share, with regard to the actual market price of the common stock at the time of issuance. the market value of the common stock at the time of its issuance was less than $0.50 per share.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2009-08-24 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000018.txt Sec File: edgar/data/1457247/0001260641-09-000018-index.htm

2009-08-21 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 207668 shares at $0.5 remaining shares owned 207668

Common Stock Pro Pharmaceuticals Inc Prwp Transaction code: A Grant, award, or other acquisition

f1 on august 21, 2009, 10x fund, l.p. received 207,668 shares of common stock of the issuer in satisfaction of dividends on shares of series b-1 and b-2 convertible preferred stock owned by 10x fund, l.p. dividends on the preferred stock are payable in shares of the issuer's common stock valued at $0.50 per share, with regard to the actual market price of the common stock at the time of issuance. the market value of the common stock at the time of its issuance was less than $0.50 per share.
f2 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f3 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.


Filed on 2009-08-17 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000016.txt Sec File: edgar/data/1457247/0001260641-09-000016-index.htm

2009-08-12 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 4

Class B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-08-12 exercise price 0.5 has valueitem expiration due date 2014-08-12 underlying security shares 1200000 underlying security title Common Stock

f2 on august 12, 2009, 10x fund, l.p. purchased (a) 150,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 300,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 300,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,200,000 shares of common stock for $0.50 per share, for aggregate consideration of $300,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,250,000 shares of series b-2 preferred stock convertible into 5,000,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,500,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,500,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 10,000,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.


Filed on 2009-08-17 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000016.txt Sec File: edgar/data/1457247/0001260641-09-000016-index.htm

2009-08-12 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 4

Series A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-08-12 exercise price 0.5 has valueitem expiration due date 2014-08-12 underlying security shares 300000 underlying security title Common Stock

f2 on august 12, 2009, 10x fund, l.p. purchased (a) 150,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 300,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 300,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,200,000 shares of common stock for $0.50 per share, for aggregate consideration of $300,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,250,000 shares of series b-2 preferred stock convertible into 5,000,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,500,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,500,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 10,000,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.


Filed on 2009-08-17 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000016.txt Sec File: edgar/data/1457247/0001260641-09-000016-index.htm

2009-08-12 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares remaining shares owned 4

Series A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-08-12 exercise price 0.5 has valueitem expiration due date 2014-08-12 underlying security shares 300000 underlying security title Common Stock

f2 on august 12, 2009, 10x fund, l.p. purchased (a) 150,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 300,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 300,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,200,000 shares of common stock for $0.50 per share, for aggregate consideration of $300,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,250,000 shares of series b-2 preferred stock convertible into 5,000,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,500,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,500,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 10,000,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.


Filed on 2009-08-17 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001260641-09-000016.txt Sec File: edgar/data/1457247/0001260641-09-000016-index.htm

2009-08-12 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 150000 shares at $2 remaining shares owned 850000

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 600000 underlying security title Common Stock

f2 on august 12, 2009, 10x fund, l.p. purchased (a) 150,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 300,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 300,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 1,200,000 shares of common stock for $0.50 per share, for aggregate consideration of $300,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,250,000 shares of series b-2 preferred stock convertible into 5,000,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,500,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,500,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 10,000,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.
f1 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after august 12, 2010 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.


Filed on 2009-07-13 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000011.txt Sec File: edgar/data/1457247/0001453356-09-000011-index.htm

2009-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 3

Class B Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-06-30 exercise price 0.5 has valueitem expiration due date 2014-06-30 underlying security shares 2000000 underlying security title Common Stock

f2 on june 30, 2009, 10x fund, l.p. purchased (a) 250,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 500,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 500,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,000,000 shares of common stock for $0.50 per share, for aggregate consideration of $500,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,400,000 shares of series b-2 preferred stock convertible into 5,600,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,800,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,800,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 11,200,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.


Filed on 2009-07-13 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000011.txt Sec File: edgar/data/1457247/0001453356-09-000011-index.htm

2009-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 3

Class A-2 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-06-30 exercise price 0.5 has valueitem expiration due date 2014-06-30 underlying security shares 500000 underlying security title Common Stock

f2 on june 30, 2009, 10x fund, l.p. purchased (a) 250,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 500,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 500,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,000,000 shares of common stock for $0.50 per share, for aggregate consideration of $500,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,400,000 shares of series b-2 preferred stock convertible into 5,600,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,800,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,800,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 11,200,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.


Filed on 2009-07-13 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000011.txt Sec File: edgar/data/1457247/0001453356-09-000011-index.htm

2009-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 1 shares at $0 remaining shares owned 3

Class A-1 Warrant Right To Buy Pro Pharmaceuticals Inc Prwp exercise date 2009-06-30 exercise price 0.5 has valueitem expiration due date 2014-06-30 underlying security shares 500000 underlying security title Common Stock

f2 on june 30, 2009, 10x fund, l.p. purchased (a) 250,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 500,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 500,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,000,000 shares of common stock for $0.50 per share, for aggregate consideration of $500,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,400,000 shares of series b-2 preferred stock convertible into 5,600,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,800,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,800,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 11,200,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.


Filed on 2009-07-13 by 10x Capital Management, Llc SEC CIK 1457247 Form 4

Accession 0001453356-09-000011.txt Sec File: edgar/data/1457247/0001453356-09-000011-index.htm

2009-06-30 10x Fund Lp (CIK 1453356) through By 10x Fund Lp

Invested in Pro Pharmaceuticals Inc bought 250000 shares at $2 remaining shares owned 700000

Series B-2 Convertible Preferred Stock Pro Pharmaceuticals Inc Prwp exercise price 0.5 has valueunderlying security shares 1000000 underlying security title Common Stock

f2 on june 30, 2009, 10x fund, l.p. purchased (a) 250,000 shares of series b-2 preferred stock, (b) one class a-1 warrant to purchase 500,000 shares of common stock for $0.50 per share, (c) one class a-2 warrant to purchase 500,000 shares of common stock for $0.50 per share, and (d) one class b warrant to purchase 2,000,000 shares of common stock for $0.50 per share, for aggregate consideration of $500,000.
f3 10x fund, l.p. has direct beneficial ownership of all the securities owned by 10x fund, l.p. 10x capital management, llc, a florida limited liability company, is the general partner of 10x fund, l.p., a delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10x fund, l.p., such portion being equal to 10x capital management, llc's (a) 20% interest in the profits of 10x fund, l.p., (b) interest in any securities which are used to pay a 2% annual management fee to 10x capital management, llc, and (c) interest in one-half of the class b warrants acquired by 10x fund, l.p. in all closings other than the initial closing held on february 12, 2009, less one class b warrant which 10x capital management, llc has committed to reallocate to investors in all prior closings until each such investor has one (1) additional class b warrant for each dollar invested.
f4 10x capital management, llc disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
f5 excludes (i) up to 1,400,000 shares of series b-2 preferred stock convertible into 5,600,000 shares of common stock; (ii) class a-1 warrants exercisable to purchase up to 2,800,000 shares of common stock; (iii) class a-2 warrants exercisable to purchase up to 2,800,000 shares of common stock; and (iv) class b warrants exercisable to purchase up to 11,200,000 shares of common stock that 10x fund, l.p. may purchase from issuer within 60 days of the date hereof pursuant to a securities purchase agreement dated february 12, 2009 between issuer and 10x fund, l.p.
f1 each share of series b-2 convertible preferred stock is convertible into four shares of issuer's common stock at a conversion price of $0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) issuer, at any time after june 30, 2010 (and upon 10 days notice) if the issuer's common stock is quoted at or above $1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of issuer's common stock is in effect (subject to certain monthly volume limits). the shares of series b-2 convertible preferred stock do not expire.